Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Boehringer Ingelheim GmbH : Boehringer Ingelheim and Funxional Therapeutics announce acquisition of Funxional’s FX125L and the somatotaxin portfolio to treat inflammation

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/23/2012 | 11:04am CEST

Ingelheim, Germany and Cambridge, UK - 23 July 2012 Today, Boehringer Ingelheim, one of the world's leading pharmaceutical companies, and Funxional Therapeutics, a clinical-stage, asset-centric, private company, announced an agreement under which Boehringer Ingelheim will acquire the global rights to Funxional Therapeutics' FX125L compound and somatotaxin programme. FX125L is a small molecule to treat a broad range of inflammatory diseases and was recently studied in a Phase 2 clinical trial in patients. Boehringer Ingelheim will be responsible for all further research, development and commercialisation of FX125L. Financial details of the transaction were not disclosed.

"Boehringer Ingelheim is delighted to add another promising compound to its development pipeline of drugs for the treatment of respiratory disease, one of its most important therapeutic areas", said Prof. Klaus Dugi, Corporate Senior Vice President Medicine, "by acquiring the Funxional Therapeutics programme, we are looking forward to bringing a potential new therapy to patients, for instance those suffering from Asthma and COPD."

David Grainger, Founder and CSO of Funxional Therapeutics commented: "We are very pleased that the future development of FX125L and the somatotaxin programme will be now driven forward by Boehringer Ingelheim. They are a very impressive organisation and their people have the necessary knowledge, skills and experience to successfully develop FX125L."

Funxional Therapeutics was founded by David Grainger with initial investment from Index Ventures and Novo A/S in 2006. Ventech led the Series B financing. Index Ventures' partner and Chairman of the board, Michele Ollier said: "This acquisition is further validation of Index's business model and we congratulate the team who have delivered first class science and developed a very exciting molecule. They have done an extraordinary job of building this company."

Notes for Editors

About Somatotaxins
The somatotaxins are a new class of anti-inflammatory small molecules that exploit a new pathway discovered by FXT. This novel pathway is acting through the type-2 somatostatin receptor involved in the resolution of inflammation, and disrupted in chronic inflammatory diseases including asthma, COPD and rheumatoid arthritis. FXT's portfolio of somatotaxins exploit this pathway to deliver broad and potent anti-inflammatory activity, with different compounds optimised for topical, parenteral and oral delivery.

About Funxional Therapeutics
Funxional Therapeutics Ltd (FXT) is a privately held, clinical stage pharmaceutical company based in Cambridge, UK.

FXT's focus is on novel anti-inflammatory therapies that exploit a new pathway discovered by FXT. The lead product (FX125L, an orally available, once-daily small molecule which belongs to the new class of somatotaxins) has completed several Phase I studies in the USA. Attractive efficacy compared to existing therapeutic options, together with an adequate safety profile and dosing convenience, all position FX125L for clinical and commercial differentiation, with the potential eventually to become the first line therapy in major inflammatory diseases. Funxional Therapeutics was founded in 2005 based on intellectual property developed by Dr David Grainger and his colleagues at Cambridge University, in collaboration with Ipsen, a global specialty-driven pharmaceutical company targeting debilitating diseases in neurology, endocrinology, uro-oncology and hemophilia. Index Ventures and Novo A/S provided first round funding to initiate research and development activities. Further funding was led by Ventech.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news
Date Title
01:51a LIBERTY MEDIA CORPORATION : Announces Completion of Rights Offering
01:46a OLEO E GAS PARTICIPACOES : Suspension of General Meetings of the DIP Debentures holders
01:36a KROGER : Who bought the $13 million Texas lottery ticket in Arlington?
01:36a PULSE ELECTRONICS : Releases The Blue Dot Ultra-Small Embedded Chip Antenna
01:35a AIM CONSULTING : Honored in the Top 10 of Seattle Business Magazine's Best 100 Companies to Work For in 2016
01:31a Sonn and Erez PLC Investigating Strategic Return Notes Sold to Merrill Lynch Customers-- Former ML Brokers Called Conduct of Merrill Lynch “Borderline Crooked”
01:27a GOLDSTRIKE RESOURCES LTD. : Announces Accelerated Expiry of Warrants
01:25a Sloan, Bagley, Hatcher & Perry Attorneys Offer Comment for Media and Complimentary Consultations for Victims of Wrongful Death, Traumatic Brain Injury and Other Serious Injuries Throughout National Safety Month and This Year
01:21a AMBER ROAD : BREXIT - What Will This Mean for Global Trade?
01:17a AYALA : P20-B shelf registration gets SEC OK
Latest news
Advertisement
Hot News 
ELECTRO RENT : Platinum Equity Increases Electro Rent Purchase Price Offer to $15.50 Per Share
Incipio Group to Acquire Skullcandy; Create Leading Technology, Creative Culture and Mobile Lifestyle Company
FINISH LINE : Reports First Quarter Fiscal Year 2017 Results
SERVISFIRST BANCSHARES, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
LINCOLN NATIONAL : LGBT Employees Engaging More with Workplace Benefits Following Marriage Equality Ruling of 2015
Most Read News
06:31p Jaguar Announces Changes to the Board of Directors and Management
06:33p JPMORGAN CHASE : post-Brexit plan hinges on tone of discourse in Europe
06:16p WILLIAMS : Committed to Closing; Will Take Appropriate Actions to Enforce Its Rights under the Merger Agreement
07:12p APPLE : Russell reconstitution adds to U.S. market's volume, volatility
07:21p AMBER ROAD : BREXIT - What Will This Mean for Global Trade?
Most recommended articles
07:12p APPLE : Russell reconstitution adds to U.S. market's volume, volatility
07:06p Law firms see short-term opportunity, long-term peril in Brexit
06:34p JPMORGAN CHASE : post-Brexit plan hinges on tone of discourse in Europe
05:47p Frankfurt or bust? Wall St. bankers in London ponder life post Brexit
05:47pDJHENKEL KGAA : Hopes to Clean Up in U.S. With Sun Products Buy -- 2nd Update